Abstract:The kynurenine pathway (KP) of tryptophan metabolism has emerged in recent years as a key regulator of the production of both neuroprotective (e.g. kynurenic and picolinic acid, and the essential cofactor NAD+) and neurotoxic metabolites (e.g. quinolinic acid, 3-hydroxykynurenine). The balance between the production of the two types of metabolites is controlled by key rate-limiting enzymes such as indoleamine-2,3-dioxygenase (IDO-1), and in turn, molecular signals such as interferon-γ (IFN-γ), which activate the KP metabolism of tryptophan by this enzyme, as opposed to alternative pathways for serotonin and melatonin production. Dysregulated KP metabolism has been strongly associated with neurological diseases in recent years, and is the subject of increasing efforts to understand how the metabolites are causative of disease pathology. Concurrent with these endeavours are drug development initiatives to use inhibitors to block certain enzymes in the pathway, resulting in reduced levels of neurotoxic metabolites (e.g. quinolinic acid, an excitotoxin and N-Methyl-d-Aspartate (NMDA) receptor agonist), while in turn enhancing the bioavailability of the neuroprotective metabolites such as kynurenic acid. Neurodegenerative diseases often have a substantial autoimmune or inflammatory component; hence a greater understanding of how KP metabolites influence the inflammatory cascade is required. Additionally, challenges exist in diseases like multiple sclerosis (MS) and motor neurone disease (MND), which do not have reliable biomarkers. Clinical diagnosis can often be prolonged in order to exclude other diseases, and often diagnosis occurs at an advanced state of disease pathology, which does not allow a lengthy time for patient assessment and intervention therapies. This review considers the current evidence for involvement of the KP in several neurological diseases, in biomarkers of disease and also the parallels that exist in KP metabolism with what is known in other diseases such as HIV, Alzheimer's disease/dementia, infection, immune privilege and cardiovascular disease. This article is part of the Special Issue entitled 'The Kynurenine Pathway in Health and Disease'.

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond

Tryptophan Metabolism in Health and Disease

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives

Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer

Tryptophan and its metabolites in normal physiology and cancer etiology

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors

Tryptophan metabolism and kynurenine metabolites in cancer: systemic nutritional and metabolic implications

Tryptophan Metabolism in Central Nervous System Diseases: Pathophysiology and Potential Therapeutic Strategies

Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities

Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects

Tryptophan Metabolism Disorder-Triggered Diseases, Mechanisms, and Therapeutic Strategies: A Scientometric Review

Tryptophan-Degrading Enzymes in Tumoral Immune Resistance

Heme-containing Enzymes and Inhibitors for Tryptophan Metabolism

Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan

Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders

Tryptophan in health and disease

The therapeutic potential of diet on immune-related diseases: based on the regulation on tryptophan metabolism

Interactions of IDO and the Kynurenine Pathway with Cell Transduction Systems and Metabolism at the Inflammation-Cancer Interface

Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases

Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges

Tryptophan Metabolism in Inflammaging: From Biomarker to Therapeutic Target